1. Home
  2. STTK vs GIFT Comparison

STTK vs GIFT Comparison

Compare STTK & GIFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STTK
  • GIFT
  • Stock Information
  • Founded
  • STTK 2016
  • GIFT 1999
  • Country
  • STTK United States
  • GIFT United States
  • Employees
  • STTK N/A
  • GIFT N/A
  • Industry
  • STTK Biotechnology: Pharmaceutical Preparations
  • GIFT Catalog/Specialty Distribution
  • Sector
  • STTK Health Care
  • GIFT Consumer Discretionary
  • Exchange
  • STTK Nasdaq
  • GIFT Nasdaq
  • Market Cap
  • STTK 37.6M
  • GIFT 44.5M
  • IPO Year
  • STTK 2020
  • GIFT N/A
  • Fundamental
  • Price
  • STTK $0.83
  • GIFT $1.37
  • Analyst Decision
  • STTK Hold
  • GIFT Strong Buy
  • Analyst Count
  • STTK 4
  • GIFT 1
  • Target Price
  • STTK $3.00
  • GIFT $4.00
  • AVG Volume (30 Days)
  • STTK 401.8K
  • GIFT 95.7K
  • Earning Date
  • STTK 07-31-2025
  • GIFT 08-15-2025
  • Dividend Yield
  • STTK N/A
  • GIFT N/A
  • EPS Growth
  • STTK N/A
  • GIFT N/A
  • EPS
  • STTK N/A
  • GIFT N/A
  • Revenue
  • STTK $4,606,000.00
  • GIFT $89,689,155.00
  • Revenue This Year
  • STTK N/A
  • GIFT $12.22
  • Revenue Next Year
  • STTK N/A
  • GIFT N/A
  • P/E Ratio
  • STTK N/A
  • GIFT N/A
  • Revenue Growth
  • STTK 69.65
  • GIFT 6.13
  • 52 Week Low
  • STTK $0.69
  • GIFT $0.50
  • 52 Week High
  • STTK $4.99
  • GIFT $4.22
  • Technical
  • Relative Strength Index (RSI)
  • STTK 39.19
  • GIFT N/A
  • Support Level
  • STTK $0.77
  • GIFT N/A
  • Resistance Level
  • STTK $0.91
  • GIFT N/A
  • Average True Range (ATR)
  • STTK 0.08
  • GIFT 0.00
  • MACD
  • STTK -0.02
  • GIFT 0.00
  • Stochastic Oscillator
  • STTK 16.23
  • GIFT 0.00

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About GIFT RDE Inc. Common Stock

Giftify Inc through its wholly-owned subsidiary, has been in the business of connecting digital consumers, businesses and communities with dining and merchant deal options throughout the United States. The company connects digital consumers, businesses, and communities offering dining and merchant deal options nationwide restaurants, and retailers to customers. The Company buys merchant gift cards from the general public and distributors at a discount and then resells them at a markup.

Share on Social Networks: